Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Indivior    INDV   GB00BRS65X63

INDIVIOR

(INDV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
02/17/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
40(c) 36.68(c) 36(c) 35.06(c) 37.5(c) Last
1 901 273 2 353 536 1 634 205 1 391 537 1 929 263 Volume
+0.73% -8.30% -1.85% -2.61% +6.96% Change
More quotes
Financials (USD)
Sales 2020 587 M
EBIT 2020 28,1 M
Net income 2020 7,00 M
Finance 2020 443 M
Yield 2020 -
Sales 2021 654 M
EBIT 2021 79,3 M
Net income 2021 71,0 M
Finance 2021 408 M
Yield 2021 -
P/E ratio 2020 54,0x
P/E ratio 2021 3,32x
EV / Sales2020 -0,15x
EV / Sales2021 -0,08x
Capitalization 356 M
More Financials
Company
Indivior specializes in the development, production and marketing of buprenorphine based medicines intended for the treatment of addiction to opiates. 78.6% of net sales are in the United States. 
Sector
Pharmaceuticals
Calendar
04/29Earnings Release
More about the company
Surperformance© ratings of Indivior
Trading Rating : Investor Rating :
More Ratings
Latest news on INDIVIOR
02/14INDIVIOR : Holding(s) in Company
PU
02/14INDIVIOR : swings to $42m loss as its flagship drug loses its market share
AQ
02/13LONDON STOCK EXCHANGE : FTSE 100 ends winning streak as pound rises, virus fears..
RE
02/13INDIVIOR : Board Committee Changes
PU
02/13INDIVIOR : FY 2019 Financial Results Presentation
PU
02/13INDIVIOR : posts steep quarterly loss as copycat drugs bite, shares plunge
RE
02/13INDIVIOR : Announces FY 2019 Financial Results
PU
02/13INDIVIOR : Full Year 2019 Results Now Available; Leadership Presentation Today
PR
02/10INDIVIOR : to Announce and Present FY 2019 Results on February 13th
PU
01/24HLS THERAPEUTICS : Files New Drug Submission for PERSERIS in Canada
AQ
01/13AQUESTIVE THERAPEUTICS : Exceeds Top End of Guidance Range for Preliminary Unaud..
AQ
01/08C4X DISCOVERY : Full Year Results
AQ
2019C4X DISCOVERY : Altasciences appointed by Indivior to conduct Phase I clinical t..
AQ
2019INDIVIOR : revenue falls as opioid addiction drug's market share plummets
RE
2019INDIVIOR : 2019 Third Quarter and Nine Months Results Now Available; Conference ..
PR
More news
News in other languages on INDIVIOR
02/13INDIVIOR : le combat face aux opiacés est loin d'être gagné
01/13Addex verfügt über Barmittel in Höhe von 31,5 Millionen Franken
2019ZURICH STOCK EXCHANGE : Morning Briefing - Markt Schweiz
2019Addex obtient un financement supplémentaire
2019Addex erhält von Partner Indivior nochmals 800'000 USD für Forschungsprojekt
More news
Analyst Recommendations on INDIVIOR
More recommendations
Sector news : Specialty & Advanced Pharmaceuticals
02/21Marriott Hires Former Merck CIO as Tech Chief
DJ
02/21Pharmaceutical companies develop system to better track counterfeit drugs
RE
02/21DAVIDSON KEMPNER CAPITAL MANAGEMENT : Form 8.3 - Allergan Plc
DJ
02/21ALLERGAN : Form 8.3 -
DJ
02/21ABBVIE : Form 8.3 -
DJ
More sector news : Specialty & Advanced Pharmaceuticals
Chart INDIVIOR
Duration : Period :
Indivior Technical Analysis Chart | INDV | GB00BRS65X63 | MarketScreener
Technical analysis trends INDIVIOR
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 0,98  $
Last Close Price 0,49  $
Spread / Highest target 327%
Spread / Average Target 101%
Spread / Lowest Target 4,09%
EPS Revisions
Managers
NameTitle
Shaun Thaxter Chief Executive Officer & Executive Director
Howard H. Pien Chairman
Mark Crossley Executive Director, Chief Operating Officer & CFO
Christian Heidbreder Chief Scientific Officer
A. Thomas McLellan Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
INDIVIOR-3.85%356
MERCK KGAA17.75%57 597
KYOWA KIRIN CO., LTD.-1.06%12 999
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD15.04%10 731
JAZZ PHARMACEUTICALS PLC-9.69%7 666
BETTA PHARMACEUTICALS CO LTD--.--%4 711